Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Performance Evaluation of the AMS CONTINUUM™ Device
Performance Evaluation of the AMS CONTINUUM™ Device in Facilitating Vesico-Urethral Anastomosis Following a Radical Prostatectomy
Status: Enrolling
Updated:  1/24/2018
Lahey Clinic Medical Center
mi
from
Burlington, MA
Performance Evaluation of the AMS CONTINUUM™ Device
Performance Evaluation of the AMS CONTINUUM™ Device in Facilitating Vesico-Urethral Anastomosis Following a Radical Prostatectomy
Status: Enrolling
Updated: 1/24/2018
Lahey Clinic Medical Center
mi
from
Burlington, MA
Click here to add this to my saved trials
Performance Evaluation of the AMS CONTINUUM™ Device
Performance Evaluation of the AMS CONTINUUM™ Device in Facilitating Vesico-Urethral Anastomosis Following a Radical Prostatectomy
Status: Enrolling
Updated:  1/24/2018
Urologic Consultants of Southeastern Pennsylvania
mi
from
Philadelphia, PA
Performance Evaluation of the AMS CONTINUUM™ Device
Performance Evaluation of the AMS CONTINUUM™ Device in Facilitating Vesico-Urethral Anastomosis Following a Radical Prostatectomy
Status: Enrolling
Updated: 1/24/2018
Urologic Consultants of Southeastern Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Performance Evaluation of the AMS CONTINUUM™ Device
Performance Evaluation of the AMS CONTINUUM™ Device in Facilitating Vesico-Urethral Anastomosis Following a Radical Prostatectomy
Status: Enrolling
Updated:  1/24/2018
Urology San Antonio Research
mi
from
San Antonio, TX
Performance Evaluation of the AMS CONTINUUM™ Device
Performance Evaluation of the AMS CONTINUUM™ Device in Facilitating Vesico-Urethral Anastomosis Following a Radical Prostatectomy
Status: Enrolling
Updated: 1/24/2018
Urology San Antonio Research
mi
from
San Antonio, TX
Click here to add this to my saved trials
Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer
Phase I-II Study of Concurrent Adjuvant Systemic Therapy and Accelerated Radiotherapy (Over 3 Weeks)
Status: Enrolling
Updated:  1/24/2018
NYU Cancer Center
mi
from
New York, NY
Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer
Phase I-II Study of Concurrent Adjuvant Systemic Therapy and Accelerated Radiotherapy (Over 3 Weeks)
Status: Enrolling
Updated: 1/24/2018
NYU Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Biopsies of Cancer Patients for Tumor Molecular Characterization
Biopsies of Cancer Patients for Tumor Molecular Characterization
Status: Enrolling
Updated:  1/24/2018
Massachusetts General Hospital
mi
from
Boston, MA
Biopsies of Cancer Patients for Tumor Molecular Characterization
Biopsies of Cancer Patients for Tumor Molecular Characterization
Status: Enrolling
Updated: 1/24/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Stereotactic Body Radiotherapy for Liver Tumors
Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy for the Treatment of Liver Metastases and Primary Liver Tumors
Status: Enrolling
Updated:  1/24/2018
St John's Mercy Medical Center
mi
from
Saint Louis, MO
Stereotactic Body Radiotherapy for Liver Tumors
Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy for the Treatment of Liver Metastases and Primary Liver Tumors
Status: Enrolling
Updated: 1/24/2018
St John's Mercy Medical Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Randomized Phase 1/2 Evaluation of Neoadjuvant Administration of a Chemokine-Modulatory Regimen in Patients With Recurrent Resectable Colorectal Cancer
Status: Enrolling
Updated:  1/24/2018
UPMC - Hillman Cancer Center
mi
from
Pittsburgh, PA
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Randomized Phase 1/2 Evaluation of Neoadjuvant Administration of a Chemokine-Modulatory Regimen in Patients With Recurrent Resectable Colorectal Cancer
Status: Enrolling
Updated: 1/24/2018
UPMC - Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Mobile Phone Multimedia Messaging Intervention for Breast Cancer Screening
Mobile Phone Multimedia Messaging Intervention for Breast Cancer Screening: Intervention Phase
Status: Enrolling
Updated:  1/24/2018
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Mobile Phone Multimedia Messaging Intervention for Breast Cancer Screening
Mobile Phone Multimedia Messaging Intervention for Breast Cancer Screening: Intervention Phase
Status: Enrolling
Updated: 1/24/2018
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Neurological Effects of Acupuncture to Prevent Radiation-induced Xerostomia
Neurological Effects of Acupuncture to Prevent Radiation-induced Xerostomia
Status: Enrolling
Updated:  1/24/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Neurological Effects of Acupuncture to Prevent Radiation-induced Xerostomia
Neurological Effects of Acupuncture to Prevent Radiation-induced Xerostomia
Status: Enrolling
Updated: 1/24/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Neurological Effects of Acupuncture to Prevent Radiation-induced Xerostomia
Neurological Effects of Acupuncture to Prevent Radiation-induced Xerostomia
Status: Enrolling
Updated:  1/24/2018
Fudan University Cancer Hospital
mi
from
Shanghai,
Neurological Effects of Acupuncture to Prevent Radiation-induced Xerostomia
Neurological Effects of Acupuncture to Prevent Radiation-induced Xerostomia
Status: Enrolling
Updated: 1/24/2018
Fudan University Cancer Hospital
mi
from
Shanghai,
Click here to add this to my saved trials
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/24/2018
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/24/2018
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/24/2018
Rush Cancer Institute at Rush University Medical Center
mi
from
Chicago, IL
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/24/2018
Rush Cancer Institute at Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/24/2018
Evanston Northwestern Healthcare - Evanston Hospital
mi
from
Evanston, IL
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/24/2018
Evanston Northwestern Healthcare - Evanston Hospital
mi
from
Evanston, IL
Click here to add this to my saved trials
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/24/2018
Ingalls Cancer Care Center at Ingalls Memorial Hospital
mi
from
Harvey, IL
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/24/2018
Ingalls Cancer Care Center at Ingalls Memorial Hospital
mi
from
Harvey, IL
Click here to add this to my saved trials
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/24/2018
Advocate Lutheran General Cancer Care Center
mi
from
Park Ridge, IL
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/24/2018
Advocate Lutheran General Cancer Care Center
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Berkeley, CA
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Berkeley, CA
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Santa Rosa, CA
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Boynton Beach, FL
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Fort Myers, FL
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Jacksonville, FL
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Wichita, KA
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Wichita, KA
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Lexington, KY
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Lexington, KY
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Louisville, KY
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Metairie, LA
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Metairie, LA
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Baltimore, MD
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Columbia, MO
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Columbia, MO
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Latham, NY
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Latham, NY
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Hickory, NC
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Hickory, NC
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Canton, OH
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Canton, OH
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Cincinnati, OH
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Greenville, SC
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Greenville, SC
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Chattanooga, TN
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Nashville, TN
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Amarillo, TX
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Amarillo, TX
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Garland, TX
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Garland, TX
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Webster, TX
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Webster, TX
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Fairfax, VA
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Fairfax, VA
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Norfolk, VA
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Richmond, VA
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Burien, WA
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Burien, WA
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Yakima, WA
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Yakima, WA
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
mi
from
Ciudad de Buenos Aires,
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
mi
from
Ciudad de Buenos Aires,
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Port Saint Lucie, FL
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Port Saint Lucie, FL
Click here to add this to my saved trials
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated:  1/24/2018
Clinical Research Facility
mi
from
Saint Louis, MO
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy
Status: Enrolling
Updated: 1/24/2018
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Spirituality/Religiosity in Patients and Caregivers
A Preliminary Study of Spirituality/Religiosity, Symptom Distress and Quality of Life Among Palliative Care Patients and Their Primary Caregivers
Status: Enrolling
Updated:  1/24/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Spirituality/Religiosity in Patients and Caregivers
A Preliminary Study of Spirituality/Religiosity, Symptom Distress and Quality of Life Among Palliative Care Patients and Their Primary Caregivers
Status: Enrolling
Updated: 1/24/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma
A Phase II Study of Weekly Oxaliplatin and Irinotecan in the Treatment of Recurrent or Metastatic Esophageal Carcinoma and Carcinoma of the Gastroesophageal (GE) Junction
Status: Enrolling
Updated:  1/24/2018
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma
A Phase II Study of Weekly Oxaliplatin and Irinotecan in the Treatment of Recurrent or Metastatic Esophageal Carcinoma and Carcinoma of the Gastroesophageal (GE) Junction
Status: Enrolling
Updated: 1/24/2018
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
A Phase II Trial of CyberKnife Stereotactic Radiosurgery to Prostate Tumors
Prospective Evaluation of CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer: Emulating Homogenous Dose Distribution
Status: Enrolling
Updated:  1/24/2018
Community Cancer Center
mi
from
Normal, IL
A Phase II Trial of CyberKnife Stereotactic Radiosurgery to Prostate Tumors
Prospective Evaluation of CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer: Emulating Homogenous Dose Distribution
Status: Enrolling
Updated: 1/24/2018
Community Cancer Center
mi
from
Normal, IL
Click here to add this to my saved trials
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
A Phase I Trial of Epirubicin, Carboplatin and Capecitabine in Adult Cancer Patients
Status: Enrolling
Updated:  1/24/2018
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
A Phase I Trial of Epirubicin, Carboplatin and Capecitabine in Adult Cancer Patients
Status: Enrolling
Updated: 1/24/2018
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma
A Single Institution, Open-Label, Nonrandomized Pilot Study of High Dose Epoetin Alfa Administered Once a Week in Patients With Multiple Myeloma: Its Effects on Hemoglobin, Blood Transfusion Requirements and Quality of Life
Status: Enrolling
Updated:  1/24/2018
Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma
A Single Institution, Open-Label, Nonrandomized Pilot Study of High Dose Epoetin Alfa Administered Once a Week in Patients With Multiple Myeloma: Its Effects on Hemoglobin, Blood Transfusion Requirements and Quality of Life
Status: Enrolling
Updated: 1/24/2018
Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials